Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.540
-0.050 (-3.14%)
At close: Dec 5, 2025, 4:00 PM EST
1.610
+0.070 (4.55%)
After-hours: Dec 5, 2025, 7:34 PM EST
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 6.25, with a low estimate of 5.00 and a high estimate of 7.50. The average target predicts an increase of 305.84% from the current stock price of 1.54.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +224.68% | Dec 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +289.61% | Dec 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $6 | Strong Buy | Maintains | $8 → $6 | +289.61% | Oct 30, 2025 |
| BTIG | BTIG | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +224.68% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +419.48% | Jun 4, 2025 |
Financial Forecast
Revenue This Year
244.09M
from 160.18M
Increased by 52.38%
Revenue Next Year
298.89M
from 244.09M
Increased by 22.45%
EPS This Year
0.04
from -0.33
EPS Next Year
0.13
from 0.04
Increased by 189.77%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 267.1M | 329.2M | ||||
| Avg | 244.1M | 298.9M | ||||
| Low | 219.5M | 252.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 66.8% | 34.9% | ||||
| Avg | 52.4% | 22.5% | ||||
| Low | 37.0% | 3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.12 | 0.29 | ||||
| Avg | 0.04 | 0.13 | ||||
| Low | -0.03 | -0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 555.1% | ||||
| Avg | - | 189.8% | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.